Lantern Pharma, a biotech redeveloping abandoned drugs for non-small cell lung cancer, raised $26 million by offering 1.8 million shares at $15, the low end of the range of $15 to $17. Lantern Pharma plans to list on the Nasdaq under the symbol LTRN. ThinkEquity acted as a lead manager on the deal.
